NCT06731218View on ClinicalTrials.gov

Phase I Clinical Study to Evaluate the Safety and Efficacy of RGB-5088 in Patients With Type 1 Diabetes Mellitus

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2031

Conditions
Diabetes Mellitus, Type 1Diabetes Mellitus
Interventions
BIOLOGICAL

RGB-5088

Transplantation under the anterior rectus sheath

Trial Locations (1)

300000

RECRUITING

Tianjin First Center Hospital, Tianjin

All Listed Sponsors
lead

Hangzhou Reprogenix Bioscience, Inc

INDUSTRY